The Minimum Clinically Important Improvement and Patient-acceptable Symptom State in the BASDAI and BASFI for Patients with Ankylosing Spondylitis

From the Department of Rheumatology, Leiden University Medical Center, Leiden; Department of Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, Amsterdam; Arthritis Center Twente, Medisch Spectrum Twente, University Twente, Enschede, the Netherlands; Department of Rheumatology B, Paris-Descartes University, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, UMR 1123; INSERM, UMR 1123, CIC-EC 1425; APHP, Hôpital Bichat, Département d’Epidémiologie et Recherche Clinique; INSERM, U738; AP-HP, Hôpital Hôtel-Dieu, Centre d’Epidémiologie Clinique; Université Paris Descartes; Pfizer SAS, Paris, France; School of Medicine, University of Queensland, Royal Brisbane and Women’s Hospital, Brisbane, Australia; Departments of Medicine and Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland; Boston University School of Medicine, Boston, Massachusetts, USA; Rheumatology Department, Hospital Universitario La Paz, Universidad Autónoma Madrid, Madrid, Spain; Hotel-Dieu de France Hospital, Saint Joseph University, Rheumatology Department, Beirut, Lebanon; Division of Rheumatology, Department of Health Policy, Management, and Evaluation, University of Toronto; Division of Clinical Decision Making and Health Care, Toronto General Research Institute, University Health Network; Institute for Work and Health; Mount Sinai Hospital, Toronto, Ontario, Canada; Mohammed Vth University, LIRPOS URAC30, Rheumatology and Physical Rehabilitation Department, El Ayachi Hospital, Salé, Morocco; Department of Experimental and Clinical Medicine, Division of Rheumatology AOUC, University of Florence, Florence, Italy.